> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# AnaBios, FDA Study Human Primary Cardiomyocytes
- URL: https://www.fdaweb.com/anabios-fda-study-human-primary-cardiomyocytes/
- Published: 2020-03-10T12:00:00.000Z
- Updated: 2026-09-14T16:06:29.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5146290

AnaBios and FDA have reached a research collaboration agreement to study adult human primary cardiomyocytes as a reference for cellular properties and drug-induced effects on cardiac function. Under the agreement, CDER and AnaBios will evaluate “functional human primary cardiomyocytes as standards for reference of gene expression, localization of functional proteins and sensitivity of their functional properties to inotropic drugs, i.e. those that affect the strength of cardiomyocyte contractility,” the company says.

AnaBios says it routinely conducts physiology studies employing adult human primary cardiomyocytes. “This project will provide new information about the biology of cells that play a critical role in normal and pathological human heart function,” it says. “We anticipate the results of this collaboration will significantly advance drug discovery strategies and safety pharmacology.” The collaboration will also help FDA’s ongoing effort to evaluate new drug development tools based on *in vitro* cellular systems, it says. Currently, AnaBios says, it is difficult to evaluate drug-induced variations in cardiomyocyte function and biological properties due to lack of baseline and human-specific information.